Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm, Inc. Receives Positive Feedback from FDA on KP201 Clinical Plan
Toggle Summary KemPharm, Inc. Presents Key Findings for Novel Hydromorphone Prodrug at 2012 International Conference on Opioids (link to poster presentation)
Toggle Summary KemPharm Inc. Focuses on Advanced Pain Management Franchise
Toggle Summary KemPharm, Inc. Expands Pain Therapy Pipeline with Discovery of KP511
Toggle Summary KemPharm, Inc. Expands ADHD Pipeline with Discovery of KP415
Toggle Summary KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
Toggle Summary KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD
Toggle Summary KemPharm, Inc. Files Antitrust and Other Counterclaims against Shire LLC
Toggle Summary KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP201 for Pain
Toggle Summary KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ADHD Prodrug Technology